Gene therapies are poised to revolutionize medicine, but their safety is paramount. Enter Cambridge-based Broken String Biosciences, a genomics firm striving to make these therapies safer. Recently, they secured a $15 million Series A funding round, co-led by Illumina Ventures and Mérieux Equity Partners, among others. These funds will propel their DNA break mapping platform, INDUCE-seq, towards a scalable 'Platform as a Service' (PaaS), expand its applications beyond gene editing, and bolster the company's growth, including opening a US office. The goal? To unlock the next wave of safer, more efficient, and affordable cell and gene therapies.
In a significant move, Yoann Bonnamour from Mérieux Equity Partners and Arnaud Autret from Illumina Ventures join Broken String Biosciences' Board of Directors, recognizing the platform's potential to become the gold standard for measuring off-target gene editing, a critical factor in advancing gene therapy.
Gene therapies hold immense promise, but safety is paramount. Cambridge-based Broken String Biosciences is dedicated to making gene therapies safer through its genomics technology. Recently securing a $15 million Series A funding round co-led by Illumina Ventures and Mérieux Equity Partners, among others, the company is set to expand its DNA break mapping platform, INDUCE-seq, into a scalable 'Platform as a Service' (PaaS) and broaden its applications beyond gene editing. This investment supports their mission to unlock the next wave of safer, efficient, and affordable cell and gene therapies. The addition of Yoann Bonnamour and Arnaud Autret to the company's Board of Directors signals the platform's potential to become the industry standard for measuring off-target gene editing, a pivotal step in advancing gene therapy.
